TABLE 1.
Characteristics of study participants and comparison of participants with and without available plasma samplesa
| Characteristic | Eligibleb (n = 410) | Excluded due to missing plasma samples (n = 298) | Included (n = 112) | P valuec |
|---|---|---|---|---|
| Age, yr | 33 (28–40) | 33 (28–40) | 33 (28–40) | 1.00 |
| Female | 235 (57.3%) | 170 (57.0%) | 65 (58.0%) | 0.86 |
| CD4 count, cells/mm3 | 166 (96–227) | 172 (103–241) | 156 (88–201) | 0.03 |
| MUAC, cm | 22.0 (20.4–24.0) | 22.0 (20.5–24.0) | 22.0 (20.0–24.5) | 0.74 |
| Concomitant TB | ||||
| All | 84 (20.5%) | 66 (22.1%) | 18 (16.1%) | 0.17 |
| Bacteriologically confirmed | 73/84 (86.9%) | 56/66 (84.8%) | 17 /18 (94.4%) | 0.38 |
| Clinically diagnosed | 11/84 (13.1%) | 10/66 (15.2%) | 1/18 (5.6%) | 0.17 |
| Baseline VL, log10 copies/ml | 5.2 (4.7–5.6) (n = 189) |
5.2 (4.7–5.6) (n = 109) |
5.2 (4.8–5.6) (n = 112) |
0.81 |
| ART regimen | ||||
| EFV + 3TC+TDF | 307 (74.9%) | 217 (72.8%) | 90 (80.4%) | 0.12 |
| EFV + 3TC+AZT | 20 (4.9%) | 11 (3.7%) | 9 (8.0%) | 0.07 |
| EFV + 3TC+d4T | 5 (1.2%) | 5 (1.7%) | 0 (0%) | 0.17 |
| NVP + 3TC+TDF | 45 (11.0%) | 38 (12.8%) | 7 (6.3%) | 0.06 |
| NVP + 3TC+AZT | 32 (7.8%) | 26 (8.7%) | 6 (5.4%) | 0.26 |
| NVP + 3TC+d4T | 1 (0.2%) | 1 (0.3%) | 0 (0%) | 0.54 |
a
Data presented as median (IQR) or n (%). MUAC, mid-upper arm circumference; TB, tuberculosis; VL, HIV viral load; ART, antiretroviral therapy; EFV, efavirenz; 3TC, lamivudine; TDF, tenofovir disoproxil fumarate; AZT, zidovudine; d4T, stavudine; NVP, nevirapine.
b
ART initiation <3 months from inclusion and ≥6 months follow-up.
c
Comparing Excluded due to missing plasma samples with Included using the Mann-Whitney U test for continuous variables and Chi-square test for dichotomous variables.